FY2025 · ended Dec 31, 2025 · Revenue $0 · Filed Mar 25, 2026
BeyondSpring Inc. (BYSI) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $0 and a net loss of $1.0 million. Free cash flow was -$19.8 million. As of Jun 30, 2026 it held $6.5 million in cash and investments and $171,000 in total debt.
Revenue (TTM)
$0
Net income (TTM)
$-6.68M
Operating cash flow (TTM)
$-16.75M
Free cash flow (TTM)
$-16.75M
EPS
—
Dividend per share
None
Shares outstanding
41.12M
+2.0% vs prior year
Net cash
$6.36M
as of Jun 30, 2026
Operating margin
-2756.4%
FY 2022
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- BYSI (Nasdaq)
- Fiscal year ends
- December 31
- Headquarters
- Florham Park, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1677940
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.4M | $1.4M | $180,000 |
| Operating income | -$8.9M | -$8.8M | -$37.2M | -$66.2M | -$64.2M |
| Net income | -$1.0M | -$11.1M | -$33.3M | -$64.2M | -$61.0M |
| Operating cash flow | -$19.8M | -$16.4M | -$27.5M | -$47.2M | -$43.7M |
| Free cash flow | -$19.8M | -$16.7M | -$27.5M | -$50.1M | -$43.8M |
| Total assets | $25.9M | $34.3M | $46.2M | $81.6M | $117.0M |
| Total liabilities | $49.9M | $48.6M | $49.2M | $55.3M | $25.2M |
| Stockholders' equity | -$32.2M | -$32.9M | -$6.0M | $26.7M | $88.3M |
| Cash and investments | $12.6M | $2.9M | $37.3M | $72.4M | $109.5M |
| Total debt | $320,000 | $589,000 | $5.0M | $3.6M | $4.3M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Oct 13, 2026 | Oct 13, 2026 |
| 8-K |
Current report
Acquisition or sale of assets
|
Oct 6, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Listing notice
|
Oct 2, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Sep 29, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Listing notice
|
Sep 18, 2026 | Sep 17, 2026 |
| ARS | Annual report to shareholders | Sep 3, 2026 | Dec 31, 2025 |
All 264 BeyondSpring Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.